clinical trial · NCT05918614
A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects
Kadmon, a Sanofi Company·phase1·completed·n = 8
Immune System Disorder (Healthy Volunteer)Belumosudil mesylatePlacebo
brief summary
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 500 mg oral BID dose of KD025 in healthy male and post-menopausal female participants.
started
Mar 28, 2014
primary completion
Jun 7, 2014
completion
Jun 7, 2014
last updated
Jun 26, 2023
detailed description
Up to approximately 58 days including safety follow up period of 30 days after participant is treated with the last dose of study drug.
official title
A Phase 1, Placebo-Controlled, Double-Blind Study to Examine the Safety, Tolerability, and Pharmacokinetics of 500 mg KD025 Administered Twice Daily in Healthy Male and Post-Menopausal Female Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol